Vaccines
FDA Authorizes Novavax’s Updated COVID-19 Vaccine for Emergency Use
Novavax COVID-19 Vaccine, FDA Authorization, Emergency Use, Protein-Based Vaccine, JN.1 Variant
Vaxcyte Announces Positive Phase 1/2 Results for VAX-31, Advances to Phase 3
Vaxcyte, VAX-31, pneumococcal conjugate vaccine, Phase 1/2 study, Phase 3 program, vaccine development, bacterial diseases
Pfizer and Valneva Announce Positive Phase 2 Results for Lyme Disease Vaccine Candidate VLA15
Lyme disease, VLA15, Pfizer, Valneva, vaccine development, tick-borne diseases
Vaxcyte Advances 31-Valent Pneumococcal Vaccine to Phase 3 Trials Following Positive Phase 1/2 Results
Vaxcyte, VAX-31, Pneumococcal Vaccine, Phase 3 Trials, Invasive Pneumococcal Disease, Vaccine Development
Novavax’s Updated COVID-19 Vaccine Receives FDA Emergency Use Authorization
Novavax, COVID-19 vaccine, FDA, Emergency Use Authorization, protein-based vaccine, JN.1 variant
FDA Approves Emergent’s ACAM2000 Vaccine for Mpox Prevention, Pledges 50,000 Doses to Affected Regions
FDA approval, Emergent BioSolutions, ACAM2000 vaccine, mpox prevention, vaccine donation, global health response
UCLA Receives $120 Million Donation for Immunology Research and Vaccine Development
UCLA, immunology research, vaccine development, $120 million donation, Gary Michelson, Alya Michelson, California Institute for Immunology and Immunotherapy
FDA Approves Updated Covid Vaccines for Fall Season: What You Need to Know
Covid-19 vaccines, FDA approval, updated vaccines, fall season, KP.2 strain, vaccination timing, immunity, side effects.
Bavarian Nordic Shares Surge on Strong Earnings and Major Mpox Vaccine Order Amid Global Health Emergency
Bavarian Nordic, Mpox Vaccine, Global Health Emergency, WHO, Vaccine Order, Earnings Report
FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna for Enhanced Protection
COVID-19 vaccines, FDA approval, mRNA vaccines, Pfizer, Moderna, updated vaccines, KP.2 variant, JN.1 lineage, emergency use authorization, vaccination guidelines.